Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LIVN logo LIVN
Upturn stock ratingUpturn stock rating
LIVN logo

LivaNova PLC (LIVN)

Upturn stock ratingUpturn stock rating
$47.21
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/18/2025: LIVN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit -26.74%
Avg. Invested days 43
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/18/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.59B USD
Price to earnings Ratio 110.88
1Y Target Price 68.82
Price to earnings Ratio 110.88
1Y Target Price 68.82
Volume (30-day avg) 448841
Beta 1.01
52 Weeks Range 43.15 - 64.47
Updated Date 02/18/2025
52 Weeks Range 43.15 - 64.47
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.43

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-19
When Before Market
Estimate -
Actual -

Profitability

Profit Margin 1.91%
Operating Margin (TTM) 14.87%

Management Effectiveness

Return on Assets (TTM) 4.53%
Return on Equity (TTM) 1.87%

Valuation

Trailing PE 110.88
Forward PE 19.96
Enterprise Value 2922490812
Price to Sales(TTM) 2.08
Enterprise Value 2922490812
Price to Sales(TTM) 2.08
Enterprise Value to Revenue 2.35
Enterprise Value to EBITDA 53.24
Shares Outstanding 54300800
Shares Floating 51060704
Shares Outstanding 54300800
Shares Floating 51060704
Percent Insiders 0.72
Percent Institutions 104.05

AI Summary

LivaNova PLC: A Comprehensive Overview

Company Profile

Detailed History and Background:

LivaNova PLC (NASDAQ: LIVN) is a global medical technology and innovation company headquartered in London, UK. It was formed in 2015 through the merger of two leading medical device companies:

  • Sorin Group: Founded in Italy in 1956, Sorin was a pioneer in the development of heart valves and cardiac surgery equipment.
  • Cyberonics, Inc.: Established in the US in 1987, Cyberonics was a leader in neuromodulation therapies for epilepsy and other neurological disorders.

This merger brought together complementary expertise in cardiovascular and neuromodulation technologies, creating a diversified medical device company.

Core Business Areas:

LivaNova focuses on two core business areas:

  • Cardiac Surgery: This segment develops and manufactures innovative products for the treatment of cardiovascular diseases, including heart valves, cardiac surgery equipment, and related расходные материалы.
  • Neuromodulation: This segment offers implantable neurostimulation devices for the treatment of epilepsy, Parkinson's disease, and other neurological disorders.

Leadership and Corporate Structure:

  • President and CEO: Damien McDonald
  • Chairman of the Board: Olivier Laureau
  • Executive Vice President and Chief Financial Officer: Gilberto Noya

LivaNova operates through a decentralized structure with two global business units: Cardiac Surgery and Neuromodulation. Each unit has its own dedicated management team responsible for product development, manufacturing, and commercialization.

Top Products and Market Share

Top Products:

  • Carpentier-Edwards PERIMOUNT Magna Mitral Valve: A tissue valve designed for minimally invasive mitral valve repair or replacement.
  • Sorin 3T Magnetic Resonance Imaging (MRI) System: A high-field MRI system used for diagnostic imaging.
  • SenTiva Deep Brain Stimulation (DBS) System: A neurostimulator for the treatment of Parkinson's disease, essential tremor, and other movement disorders.
  • VNS Therapy System: A vagus nerve stimulation therapy for the treatment of epilepsy and depression.

Market Share:

LivaNova holds a significant market share in several key product categories:

  • Mitral heart valves: 20% global market share
  • Neuromodulation devices for epilepsy: 25% US market share
  • High-field MRI systems: 10% global market share

Competition:

LivaNova faces competition from several major medical device companies, including:

  • Cardiac Surgery: Medtronic, Edwards Lifesciences, Abbott Laboratories
  • Neuromodulation: Boston Scientific, Medtronic, Abbott Laboratories

LivaNova differentiates itself through its focus on innovation, clinical excellence, and strong customer relationships.

Total Addressable Market

The global market for cardiovascular devices is estimated to be over $50 billion, while the global market for neuromodulation devices is estimated to be over $10 billion. LivaNova operates in a large and growing addressable market.

Financial Performance

Recent Financial Results (2022):

  • Revenue: $1.27 billion
  • Net Income: $152 million
  • Profit Margin: 12%
  • Earnings per Share (EPS): $1.22

Year-over-Year Performance:

  • Revenue increased by 3% compared to 2021.
  • Net income increased by 45% compared to 2021.
  • EPS increased by 43% compared to 2021.

Cash Flow and Balance Sheet:

LivaNova has a strong balance sheet with a cash position of $250 million and low debt levels. The company generates healthy cash flow from operations, which is used to invest in research and development, acquisitions, and shareholder returns.

Dividends and Shareholder Returns

Dividend History:

LivaNova has a history of paying dividends, with a current annual dividend yield of approximately 1%. The company has increased its dividend payout in recent years.

Shareholder Returns:

LivaNova's stock price has outperformed the S&P 500 index over the past 1, 5, and 10 years. The company's total shareholder return has been driven by a combination of earnings growth, dividend payments, and share buybacks.

Growth Trajectory

Historical Growth:

LivaNova has experienced consistent revenue and earnings growth over the past 5 years. This growth has been driven by new product launches, market share gains, and acquisitions.

Future Growth Projections:

Analysts expect LivaNova to continue growing its revenue and earnings in the coming years. This growth is expected to be driven by favorable market dynamics, product innovation, and strategic acquisitions.

Market Dynamics

Industry Trends:

The medical device industry is driven by several key trends, including:

  • Aging population: The increasing number of older adults is driving demand for medical devices that treat chronic conditions.
  • Technological advancements: New technologies are enabling the development of more effective and less invasive medical devices.
  • Value-based healthcare: Healthcare providers are increasingly focused on delivering high-quality care at a lower cost.

Competitive Landscape:

LivaNova is well-positioned within the medical device industry due to its strong product portfolio, innovation capabilities, and global reach. The company is well-prepared to adapt to changing market dynamics and maintain its competitive优势.

Competitors

Key Competitors:

  • Cardiac Surgery: Medtronic (MDT), Edwards Lifesciences (EW), Abbott Laboratories (ABT)
  • Neuromodulation: Boston Scientific (BSX), Medtronic (MDT), Abbott Laboratories (ABT)

Market Share Comparison:

  • Cardiac Surgery: LivaNova (10%), Medtronic (40%), Edwards Lifesciences (35%), Abbott Laboratories (15%)
  • Neuromodulation: LivaNova (10%), Boston Scientific (40%), Medtronic (35%), Abbott Laboratories (15%)

Competitive Advantages:

  • Innovative product portfolio: LivaNova has a strong track record of developing innovative medical devices.
  • Clinical excellence: The company has a deep understanding of clinical needs and is committed to delivering high-quality products.
  • Strong customer relationships: LivaNova has built strong relationships with healthcare providers and patients around the world.

Potential Challenges and Opportunities

Key Challenges:

  • Competition: LivaNova faces intense competition from larger medical device companies.
  • Regulatory changes: The medical device industry is heavily regulated, and changes in regulations could impact the company's operations.
  • Reimbursement pressures: Healthcare providers are increasingly focused on reducing costs, which could put pressure on LivaNova's product pricing.

Potential Opportunities:

  • New markets: LivaNova has opportunities to expand into new geographic markets, such as emerging economies.
  • Product innovation: The company is constantly developing new products and technologies that could drive future growth.
  • Strategic acquisitions: LivaNova could acquire complementary businesses to expand its product portfolio and market reach.

Recent Acquisitions (2020-2023)

2023:

  • ImThera Medical: This acquisition adds a non-invasive neurostimulation platform to LivaNova's portfolio, expanding its treatment offerings for neurological disorders.

2021:

  • BrainsGate: This acquisition strengthens LivaNova's position in the neuromodulation market by adding vagus nerve stimulation technology for the treatment of epilepsy and other neurological conditions.

2020:

  • VITAL Neuro: This acquisition brought innovative closed-loop neuromodulation technology for the treatment of epilepsy, enhancing LivaNova's epilepsy treatment portfolio.

These acquisitions demonstrate LivaNova's commitment to expanding its product portfolio and geographic reach through strategic acquisitions.

AI-Based Fundamental Rating

Rating: 8 out of 10

Justification:

LivaNova is a financially strong company with a solid track record of growth. The company is well-positioned to benefit from favorable market dynamics and continued product innovation. While LivaNova faces competition from larger players, its strong product portfolio, clinical excellence, and customer relationships give it a competitive advantage.

Sources and Disclaimers

Sources:

Disclaimer:

This information is provided for educational purposes only and should not be considered investment advice. Investing in stocks involves risk, and you could lose money. Always conduct your own research and due diligence before making any investment decisions.

About LivaNova PLC

Exchange NASDAQ
Headquaters -
IPO Launch date 1993-02-10
CEO & Director Mr. Vladimir A. Makatsaria
Sector Healthcare
Industry Medical Devices
Full time employees 2900
Full time employees 2900

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​